Boston, MA 07/17/2013 (wallstreetpr) – The shares of Epizyme, Inc. (NASDAQ:EPZM) increased to close at $43.60 in trading session of Tuesday, July 16. This closing number demonstrates increase in the stock price by 8.54%. After opening at $42.09, the stock exhibited an intraday high of $44.75. Against an average volume of 171,347.00 shares in last 90 trading sessions, a higher volume of 405,704.00 shares were traded in session of Tuesday.
A clinical stage biopharmaceutical company, Epizyme, Inc. is focused on discovering, developing and planning of commercializing therapies for patients suffering from genetic cancers. Epizyme, Inc. systematically identifies the genetic alterations which cause genes that result into cancer. These genes are called oncogenes. It selects those patients who demonstrate the presence of the identified genetic alteration and then the company designs small molecule therapeutics for inhibiting these genes. The clinical research and development of its products is focused on patients with a particularly defined genetic cancer. The Company is conducting a Phase I testing of its advanced product, EPZ-5676, aimed at treating mixed lineage leukemia (MLL-r). The Company has identified two products to lead its product platform.
On July 3, 2013, Epizyme, Inc. appointed Jason P. Rhodes as its president. Before holding the position as the President, Rhodes has served the Company, Epizyme, Inc. as Chief Financial Officer and Executive Vice President. Along with the post of the President, Rhodes is continuing as the role of Chief Financial Officer and reports to the Chief Executive Officer of Epizyme, Inc., Dr Robert J. Gould, PhD. Prior to this, Rhodes has served as Vice President, Business Development, at Alnylam Pharmaceuticals, Inc. and as a founder and partner of Fidelity Biosciences.
